Tunç LAÇİN, İrfan YALÇINKAYA, Mustafa VAYVADA, Talha DOĞRUYOL, Serdar EVMAN, Levent ALPAY, Hakan KIRAL, Volkan BAYSUNGUR

Survival in adenosquamous cancer of the lung: is it really so unfavorable?

Amaç: Bu tek merkezli çalışmada, akciğer adenoskuamözkanseri (AAK) nedeni ile ameliyat edilmiş hastaların sağkalımoranları ile adenokarsinom veya skuamöz hücreli karsinomnedeni ile ameliyat edilmiş hastaların sağkalım oranları arasındaanlamlı bir farklılık olup olmadığı araştırıldı. Çalışmaplanı: Ocak 2002 - Ocak 2011 tarihleri arasındahastanemizde küçük hücreli dışı akciğer kanseri nedeni ileameliyat edilen toplam 2203 hasta (1977 erkek, 226 kadın; ort.yaş 57.8±34.9 yıl; dağılım 22-86 yıl) patolojik tanı, sağkalım vetümör evresi yönünden retrospektif olarak analiz edildi. Bul gu lar: Patolojik analiz sonucunda, 2203 hastanın46sında (%2.1) adenoskuamöz kanser tanısı doğrulandı.Ortanca sağkalım süresi adenokarsinom için 53.6 ay(dağılım 21.1-68.2 ay), skuamöz hücreli karsinom için48.1 ay (dağılım 24.4-66.9 ay) ve AAK için 27.9 ay idi(dağılım 10.7-44.6 ay) (p=0.026). Ortanca sağkalım süresiadenokarsinom predominansı olan hasta grubunda 21.6 ay,skuamöz hücreli karsinom predominansı olan hasta grubunda21.4 ay, kodominant hücre dizisi olan hasta grubunda 37.8 ayidi (p=0.007). So nuç: Çalışmamızda, AAK hastalarının sağkalımoranı skuamöz hücreli karsinom veya adenokarsinomhastalarınınkinden daha düşük idi. Cerrahi rezeksiyon sonrasıadjuvan kemoradyoterapinin genel sağkalım oranlarını iyileştiripiyileştirmediğini araştıracak ileri klinik çalışmalar gereklidir.

Akciğerin adenoskuamöz kanserinde sağkalım: Gerçekten o kadar kötü mü?

Background: This single-center study aims to investigatewhether a significant difference exits between the survivalrates of patients operated for adenosquamous cancer of the lung(ASCL) and patients operated for adenocarcinoma or squamouscell carcinoma. Methods: A total of 2,203 patients (1,977 males, 226 females;mean age 57.8±34.9 years; range 22 to 86 years) operated fornon-small cell lung cancer in our hospital between January 2002and January 2011 were retrospectively analyzed for pathologicaldiagnosis, survival, and tumor staging. Results: As a result of pathological analysis, the diagnosis ofadenosquamous cancer was confirmed in 46 out of 2,203 (2.1%)patients. The median survival time was 53.6 months (range 21.1to 68.2 months) for adenocarcinoma, 48.1 months (range 24.4 to66.9 months) for squamous cell cancer, and 27.9 months (range10.7 to 44.6 months) for ASCL (p=0.026). The median survivaltime was 21.6 months in the group of patients with predominatingadenocarcinoma, 21.4 months in the group of patients withpredominating squamous cell carcinoma, and 37.8 months in thegroup of patients with codominant cell lines (p=0.007). Conclusion: In our study, the survival rate of ASCL patientswas lower than that of patients with squamous cell carcinomaor adenocarcinoma. Further clinical studies are needed toinvestigate whether adjuvant chemoradiotherapy followingsurgical resection improves overall survival rates.

PDF

___

1. Gawrychowski J, Brulinski K, Malinowski E, Papla B. Prognosis and survival after radical resection of primary adenosquamous lung carcinoma. Eur J Cardiothorac Surg 2005;27:686-92.
2. Maeda H, Matsumura A, Kawabata T, Suito T, Kawashima O, Watanabe T, et al. Adenosquamous carcinoma of the lung: surgical results as compared with squamous cell and adenocarcinoma cases. Eur J Cardiothorac Surg 2012;41:357-61.
3. Kamiyoshihara M, Hirai T, Kawashima O, Ishikawa S, Morishita Y, Maeshima A. A clinicopathologic study of the resected cases of adenosquamous carcinoma of the lung. Oncol Rep 1998;5:861-5.
4. Hsia JY, Chen CY, Hsu CP, Shai SE, Wang PY. Adenosquamous carcinoma of the lung. Surgical results compared with squamous cell and adenocarcinoma. Scand Cardiovasc J 1999;33:29-32.
5. Hofmann HS, Knolle J, Neef H. The adenosquamous lung carcinoma: clinical and pathological characteristics. J Cardiovasc Surg (Torino) 1994;35:543-7.
6. Nakagawa K, Yasumitu T, Fukuhara K, Shiono H, Kikui M. Poor prognosis after lung resection for patients with adenosquamous carcinoma of the lung. Ann Thorac Surg 2003;75:1740-4.
7. Travis WD, Brambilla E, Muller-Hermenlink HK, Harris CC. World Health Organization Classification of Tumors. Pathology and genetics of tumors of the lung, pleura, thymus and heart. Lyon: International Agency for Research on Cancer Press; 2004.
8. Shimosato Y. Pulmonary neoplasms. In: Sternberg SS, editor. Diagnostic surgical pathology. Vol. 1. New York: Raven Press; 1989. p. 785-27.
9. Ichinose Y, Hara N, Takamori S, Maeda K, Yano T, Ohta M. DNA ploidy pattern of each carcinomatous component in adenosquamous lung carcinoma. Ann Thorac Surg 1993;55:593-6.
10. Goldstraw P. IASLC Staging Manual in Thoracic Oncology. Orange Park: Editorial Rx Press; 2009.
11. Sridhar KS, Bounassi MJ, Raub W Jr, Richman SP. Clinical features of adenosquamous lung carcinoma in 127 patients. Am Rev Respir Dis 1990;142:19-23.
12. Naruke T, Tsuchiya R, Kondo H, Asamura H. Prognosis and survival after resection for bronchogenic carcinoma based on the 1997 TNM-staging classification: the Japanese experience. Ann Thorac Surg 2001;71:1759-64.
13. Takamori S, Noguchi M, Morinaga S, Goya T, Tsugane S, Kakegawa T, et al. Clinicopathologic characteristics of adenosquamous carcinoma of the lung. Cancer 1991;67:649-54.
14. Cooke DT, Nguyen DV, Yang Y, Chen SL, Yu C, Calhoun RF. Survival comparison of adenosquamous, squamous cell, and adenocarcinoma of the lung after lobectomy. Ann Thorac Surg 2010;90:943-8.
15. Mordant P, Grand B, Cazes A, Foucault C, Dujon A, Le Pimpec Barthes F, et al. Adenosquamous carcinoma of the lung: surgical management, pathologic characteristics, and prognostic implications. Ann Thorac Surg 2013;95:1189-95.
16. Colby TV, Koss MN, Travis WD. Tumors of the lower respiratory tract. In: Atlas of Tumor Pathology. 3rd ed. Washington: Armed Forces Institute of Pathology; 1995. p. 279-86.